Intercell plans additional Pseudomonas trial, Novartis delays option decision
This article was originally published in Scrip
Intercell, Europe's leading independent vaccine developer, has unveiled plans to run an additional efficacy trial of its candidate Pseudomonas aeruginosa vaccine. The move, which is being financially supported by its development partner Novartis, will delay the pharma company's decision whether to opt-in into the programme. The new Phase II trial will be powered to show efficacy in intensive care unit patients.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.